Mauna Kea Technologies today announced first half 2021 financial results for the six months ended June 30, 2021. First Half 2021 Financial...
Mauna Kea Technologies reports first half 2021 financial results
read more
Search Results
Mauna Kea Technologies Announces New Clinical Study and Research Collaboration Agreement with the Lung Cancer Initiative at Johnson & Johnson
Mauna Kea Technologies (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal...
Mauna Kea Technologies announces a capital increase of approximately €12.5 million reserved for two investors
This transaction by issuance of Units allows the Company to secure its financing until the end of the third quarter of 2022 Mauna Kea...
Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent
The next-generation Cellvizio® platform is now cleared for use with fluorescein dye to image blood flow in the microvasculature and capillaries...
Mauna Kea Technologies Reports Second Quarter and First Half of 2021 Sales
Mauna Kea Technologies today announced second quarter and first half 2021 sales results for the three and six-month periods ended June 30,...
Mauna Kea Technologies Announces Completion of Enrollment of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy
The study combining Cellvizio® with the AQ-Flex™ 19 Confocal Miniprobe™ and the Monarch® Platform from Auris Health, Inc.,...
Mauna Kea Technologies Announces Positive Results on Needle-Based Endomicroscopy as a Real-Time Detection Tool for Lung Cancer
New peer-reviewed evidence in the prestigious Thorax journal shows lung cancer can be accurately diagnosed with Cellvizio® AQ-Flex™ 19...
Mauna Kea Technologies Announces a New Publication in Nature Scientific Reports Demonstrating the Accuracy of Cellvizio® for Food Allergy Diagnosis
New peer-reviewed evidence that Cellvizio can be used as a screening tool in patients with suspected food allergy Mauna Kea...
Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform
Launch of the new system is part of the company’s mission to deliver an enhanced platform combining advanced imaging, digital health...
Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio® in Gastrointestinal Diseases at Digestive Disease Week® (DDW) 2021 Virtual™
Further validation of how the use of Cellvizio potentially impacts patient management and improves outcomes in multiple gastrointestinal...
Mauna Kea Technologies Announces it has Signed its 15th Hospital in Europe for Irritable Bowel Syndrome (IBS) Food Allergy Application
Confirming the Role and added value of Cellvizio for the Identification and Management of IBS Patients with Atypical Food Allergies Mauna Kea...
Mauna Kea Technologies reports second half and full year 2020 financial results and first quarter of 2021 sales
Strong 2H’20 financial results driven by 27% sales growth and a 15% reduction in net loss compared to prior year period The Company...